Hua Medicine Completes $117 Million Funding for Novel Diabetes Treatment

Shanghai 's Hua Medicine closed a combined Series D & Series E financing of $117.4 million, which the company says will be enough to fund two clinical trials and commercial launch of its novel oral treatment for type 2 diabetes in China. The candidate, dorzagliatin (HMS5552), is a novel first-in-class, 4th-generation glucokinase activator (GKA). It works by improving the reaction of impaired blood glucose sensors, producing insulin in response to higher glucose levels. Hua expects China approval of dorzagliatin in 2020. More details.... Share this with colleagues: // //